• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Ardelyx (ARDX) Could Be 76% Undervalued As Kidney Week Puts Focus Back On Valuation

    Simply Wall St·10/29/2026 08:38:35
    Listen to the news

    Ardelyx (ARDX) is back in front of kidney specialists as management presents at the American Society of Nephrology Kidney Week 2026 in Denver, giving investors fresh clinical context for its dialysis focused franchise.

    Ardelyx’s presentation lands after a choppy run for the stock, with a 1-day share price return of 3.33% offering a brief lift against a year-to-date share price decline of 49.59% and a 1-year total shareholder return that is down 37.50%.

    Compare Ardelyx’s volatility with other potential turnaround stories by scanning our curated list of 19 high quality undiscovered gems before making your next move in the sector.

    Ardelyx now has a clearer kidney-focused story and a sharply lower share price after a tough year. The key question is straightforward: does this business profile justify a US$3.10 share price today?

    Most Popular Narrative: 76% Undervalued

    Against Ardelyx’s last close at $3.10, the most widely followed narrative puts fair value at $12.90. This frames the recent share slide as a large gap between current pricing and modeled expectations that investors now have to judge for themselves.

    The rising prevalence of chronic kidney disease (CKD) and gastrointestinal disorders driven by an aging population continues to expand Ardelyx's core addressable markets, supporting sustained long-term demand for IBSRELA and XPHOZAH and driving future revenue growth. Recent and ongoing improvements in market access, prescription pull-through, and expansion of the sales force are boosting prescriber breadth and depth, contributing to accelerating product adoption and positioning the company to achieve strong topline growth and improved gross margins as fixed costs are leveraged.

    See why 74 investors see Ardelyx as 76% undervalued.

    According to this widely followed view, a fair value of $12.90 per share reflects revenue growth assumptions of about 28.5% a year, a future profit margin near 29.2% and a discount rate of 7.91% applied to those cash flows. The same framework also leans on earnings forecasts that move from a current loss of $55.7 million to $279.2 million by around 2029, using a P/E of 15.6x at that point to back into today’s valuation.

    That creates a wide range of outcomes for Ardelyx because analyst estimates for 2029 earnings stretch from $105.1 million to $481.0 million. The spread underlines that investors are effectively taking a view on how payer behavior, prescription momentum and operating costs will play out rather than working off a single clean number.

    Result: Fair Value of $12.90 (UNDERVALUED)

    Still, the story can flip quickly if payer restrictions on XPHOZAH and IBSRELA tighten further, or if Ardelyx faces setbacks tied to its concentrated product lineup.

    Find out about the key risks to this Ardelyx narrative.

    Next Steps

    This mix of sharp downside and bullish valuation work has split opinion on Ardelyx. Move quickly, review the numbers yourself, and weigh up the 4 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond Ardelyx?

    If you stop with Ardelyx, you could miss other setups that better match your risk, income, or value priorities. Put a wider opportunity set on your radar.

    • Target higher income potential by scanning companies in the 6 dividend fortresses that combine yield with more resilient payout profiles.
    • Hunt for mispriced opportunities through the 26 high quality undervalued stocks that filters for strong fundamentals at what may be compressed valuations.
    • Dial back risk while staying invested by reviewing the 32 resilient stocks with low risk scores that highlights businesses with more resilient balance sheets and stability metrics.